Immunological checkpoint inhibitor | Combined drug | Application | Number of volunteers | OS (months) | Rate of OS (at 6 months) | ORR (%) | DOR (months) | PFS (months) |
---|---|---|---|---|---|---|---|---|
pembrolizumab | Epacadostat [168] | Unresectable or metastatic melanoma | 354 | – | 84.1 | 34.2 | – | 4.70 |
Pomalidomide+Dexamethasone [169] | Refractory or relapsed and refractory multiple myeloma | 126 | 21.0 (14.2-NA) | – | – | – | 5.7 | |
nivolumab | Previously untreated advanced melanoma | 313 | – | 0.86 | 57.6 | – | 11.50 | |
Previously untreated advanced or metastatic renal cell carcinoma | 550 | – | – | 38.7 | – | 12.42 | ||
ipilimumab | Sargramostim [172] | stage III or stage IV melanoma untreatable by surgery | 123 | 17.5 (14.9-NA) | – | – | – | 3.10 |
Dacarbazine [173] | untreated unresectable stage III or IV melanoma | 250 | 11.17 | – | – | 19.3 | 2.76 | |
Paclitaxel/ Carboplatin [174] | Lung cancer—non small cell squamous | 388 | 13.37 | – | – | – | 5.55 | |
Nab-Paclitaxel + Carboplatin [175] | Non-squamous non-Small cell lung cancer | 483 | 18.6 | – | – | – | 7.00 | |
atezolizumab | Carboplatin + Etoposide [176] | Untreated extensive-stage small cell lung cancer | 201 | 12.3 | – | – | – | 5.2 |
Cobimetinib [177] | Metastatic colorectal adenocarcinoma | 183 | 8.87 | – | – | 1.97 | 1.91 | |
Bevacizumab [178] | Renal cell carcinoma | 178 | – | – | – | – | 8.90 |